Covalon Technologies (CVE:COV) and ImmunoPrecise Antibodies (CVE:IPA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, dividends, analyst recommendations and profitability.
Analyst Recommendations
This is a breakdown of current ratings for Covalon Technologies and ImmunoPrecise Antibodies, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Covalon Technologies | 0 | 0 | 0 | 0 | N/A |
ImmunoPrecise Antibodies | 0 | 0 | 0 | 0 | N/A |
Earnings and Valuation
This table compares Covalon Technologies and ImmunoPrecise Antibodies' revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Covalon Technologies | C$23.84 million | 1.68 | C$-6,144,922.00 | C($0.24) | -6.51 |
ImmunoPrecise Antibodies | C$17.18 million | 13.08 | C$-4,082,906.00 | C($0.21) | -55.05 |
ImmunoPrecise Antibodies has lower revenue, but higher earnings than Covalon Technologies. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than Covalon Technologies, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Covalon Technologies and ImmunoPrecise Antibodies' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Covalon Technologies | N/A | N/A | N/A |
ImmunoPrecise Antibodies | N/A | N/A | N/A |
Summary
ImmunoPrecise Antibodies beats Covalon Technologies on 3 of the 5 factors compared between the two stocks.